Welcome to
Chemical Collective

Are you 18 or older?

Please confirm that your are 18 years of age or older.

You are not allowed to access the page.

I am 18+

EXIT

SALE NOW ON!

PSYCH NEWS – 28/07/2025

By David Blackbourn

MindMed MM-120 Receives FDA Breakthrough Designation for GAD
HHC Potency Found to be Comparable to THC
Psychoactive Drug Pollutants Accumulate in Fish Eyes
Sheffield University Studies Psychedelic Use Throughout History
5-MeO-DMT Nasal Spray Trial Shows Antidepressant Effect
Māori Representatives Present Indigenous Knowledge at Psychedelic Conference
Structure of LSD Bound to 5-HT2A Receptor Determined
Psilocybin Reduces Depression in Cancer Patients

6 minute read

0 Last updated July 28th, 2025

By David Blackbourn

Disclaimer: The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of Chemical Collective or any associated parties.

This week’s developments in psychedelics news and research around the world show the continuing and wide-ranging effects of a “psychedelic renaissance” in full swing. Major strides are being made in developing new mental health treatments for a variety of depressive conditions, from LSD to 5-MeO-DMT for GAD/MDD, and psilocybin for depression in cancer patients. Alongside this, crucial cultural conversations are underway, surrounding the impact of the growing psychedelics industry on indigenous populations. Research is even shedding light on the historical and current effects of psychoactive substances on the development of urban spaces.

MindMed MM-120 Receives FDA Breakthrough Designation for GAD

The biotech firm MindMed has begun treatment of patients in its Phase 3 clinical trial for MM-120. MM-120 is a proprietary formulation of lysergic acid diethylamide (LSD), which is being studied for its potential to treat generalised anxiety disorder (GAD). The study is a randomised, double-blind, placebo-controlled trial to determine the optimum dosage of MM-120 in this context. The effectiveness of the compound will be monitored over a 12-week period to determine its efficacy for treating GAD, when compared to other current solutions.

The prior phases of the trial have already demonstrated a significant clinical benefit. As a result, the U.S. Food and Drug Administration (FDA) has granted MM-120 designation as a “Breakthrough Therapy”. This is an exciting development for the team at MindMed, as breakthrough designation is intended to expedite the development and review process required to bring promising drug treatments to the public.

HHC Potency Found to be Comparable to THC

A new study has found that the semi-synthetic cannabinoid, hexahydrocannabinol (HHC), has psychoactive effects which are much more powerful than initially believed. HHC recently appeared in the exceedingly grey area of the recreational drug market and is often sold as a legal replacement for THC. Users primarily consume HHC for recreational purposes, but adverse effects have been reported.

Little is known about the chemistry of the substance as of yet. The research carried out by Italy’s National Institute of Health revealed that HHC’s potency is comparable to that of THC. This challenges the perspective, often used as a selling point, that HHC is a milder alternative.

The study used lab analysis to measure HHC’s interaction with cannabinoid receptors, as well as monitoring behavioural changes in mice administered the substance. They observed significant psychoactive effects in both contexts, which raises concerns about safety and potential regulation. More public awareness and scrutiny around cannabis alternatives is seemingly required.

Psychoactive Drug Pollutants Accumulate in Fish Eyes

A study published in Environmental Science & Technology Letters has reported that psychoactive drugs that are common pollutants in aquatic environments accumulate in the eyes of fish. Researchers studying European perch discovered that high concentrations of these contaminants were significantly higher in the fish’s eyes, as opposed to their brain tissue.

The accumulation of these substances in the eyes was found to affect the levels of neurotransmitters, which are critical for visual processing. This suggests that this pollution is directly and seemingly negatively affecting the fish’s physiology and sensory capabilities.

The study appears to reveal just how much we are underestimating the ecological harm caused by pharmaceutical contaminants. The researchers concluded that the methods we currently use to monitor aquatic pollution are insufficient and called for further research to include sensory function as a key indicator of pollution’s environmental effects.

Sheffield University Studies Psychedelic Use Throughout History

Research from Sheffield University has explored the wide-ranging impact of what they call the “psychoactive revolution” on the development of society and the shape of our public spaces. The research revealed the economic, even architectural impact of the trafficking of intoxicants such as coffee and tobacco…into Western Europe. Urban spaces were indeed organised around psychoactive substances. The pub, the coffeeshop, for example. The impact of the industries which stemmed from the use of these substances cannot be undersold.

Dr James Brown led the research efforts and concisely explained the motivations behind the study:

It’s important to talk about the history of these intoxicants because they remain a live issue for society. There are many conversations around legal and illegal substances and the role they play in our lives…and the study of this history helps us to better understand its impact on social behaviours and therefore the ethics of these supply chains.

The wider purpose of the research was to educate the next generation. Partnering with seven schools across the UK, Sweden, Germany and the Netherlands, the team shared the research with A-level students. Events involving facilitators like artists, novelists and cartoonists provided an accessible means to relate the wider effects of psychedelics on culture. Dr Brown described the response to the research as positive:

The students responded well to the research…and showed an understanding of the origins of substances that we take for granted today. It opened up further conversations about social spaces that are important in their lives and concerns around exploitative commodity chains that are still current today.

Substances which alter consciousness have been central to cultures around the world for millennia. Art, philosophy, and our understanding of the mind as a whole have all been affected by psychedelic use.

5-MeO-DMT Nasal Spray Trial Shows Antidepressant Effect

Atai Life Sciences and its partner Beckly Psytech have announced positive results from their Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression (TRD). BPL-003 is a proprietary, short-acting formulation of 5-MeO-DMT, a substance which is around 4-6 times stronger than DMT. The treatment is administered as a nasal spray. Both 8 mg and 12 mg single doses of BPL-003 showed what the two companies described as “statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study.”

The treatment was well tolerated, and the effects of the treatment only lasted around two hours. This shorter duration potentially makes 5-Me0-DMT a more logical substance to employ in a therapeutic context. Psilocybin, for example, can last for more than double that time. If we consider that as an individual therapy session requiring monitoring throughout, preparation and subsequent integration, that is likely to be unfeasible on any kind of useful scale – at least any time soon.

A larger study is planned for later this year to confirm these initial findings and establish an optimum dosage.

Māori Representatives Present Indigenous Knowledge at Psychedelic Conference

A delegation of Māori researchers and traditional healing practitioners attended Europe’s biggest psychedelic conference to share insights from the Mātauranga Māori (traditional Māori knowledge systems). The purpose of their visit was not only to share knowledge but to ensure that indigenous worldviews are included in the global conversation around psychedelics. The effects of psychedelics on the individual are rooted in culture (set & setting), and the spiritual and communal context in which they have been taken provides valuable insight into their potential applications.

The central message of the delegation was a call for more ethical and respectful engagement with indigenous communities from the industry. Commercial interests behind a lot of research today often suppress indigenous knowledge in favour of quick-fix, rapid-to-market solutions, lacking any cultural underpinning. There are significant risks associated with the cultural appropriation of indigenous knowledge without reciprocity. Their presence served as a necessary reminder to the scientific community that honouring the existing, in-depth knowledge and deep cultural roots of these substances is paramount to their future application.

Structure of LSD Bound to 5-HT2A Receptor Determined

Research published in Cell has successfully mapped the structure of the human serotonin receptor 5-HT2A when it is activated by LSD.

Think of the 5-HT2A receptor as a chemical lock, which LSD fits into to alter the flow of serotonin in the brain, leading to its consciousness-altering effects.

Using advanced electron microscopy, scientists were able to create a detailed, three-dimensional map of exactly how it is that LSD binds to and interacts with the receptor. We have had research confirming that the majority of “classical” psychedelics (LSD, DMT, Psilocybin) interact with the 5-HT2A receptor, but the specifics of this interaction were murky at best. No longer!

This concrete, structural data provides the critical insight required to understand the effects of these substances. This can serve as a blueprint for future drug development, enabling scientists to map novel compounds more precisely to the architecture of the receptor. It will also provide a deeper understanding of the substances’ effects, for example, their length of duration, etc.

All of this knowledge will provide more precision to the application of these substances in a variety of contexts.

Psilocybin Reduces Depression in Cancer Patients

Roughly one in four people with cancer has depression. Treatment for this is difficult, especially with potential interactions between the treatment and existing medications that individuals may be prescribed. New research has revealed that just a single dose of psilocybin (the main psychedelic compound in magic mushrooms) has a long-lasting impact on cancer patients’ well-being, dramatically and safely reducing depressive symptoms for a sustained period.

The trial involved the administration of a single dose of synthetic psilocybin to individuals with both cancer and major depressive disorder. This was conducted in a clinical environment with set & setting controls and psychological support prior to and after the session. The lead author of the study, Manish Agrawal, of Sunstone Therapies, explains the long-lasting nature of the psilocybin treatment:

One dose of psilocybin with psychological support to treat depression has a long-term positive impact on relieving depression for as much as 2 years for a substantial portion of patients with cancer, and we’re exploring whether repeating the treatment resolves depression for more than half of the patients.

Continuing:

If randomized testing shows similar results, this could lead to greater use of psilocybin to treat depression in patients with cancer.

Tackling depression in cancer patients is extremely important. The existential distress associated with a cancer diagnosis is profound, and the resulting depression can actually affect the ability to tolerate potentially helpful medical treatments, and therefore their chances of survival. Psilocybin potentially offers a safe, rapid solution to these widespread issues.

David Blackbourn | Community Blogger at Chemical Collective

David is one of our community bloggers here at Chemical Collective. If you’re interested in joining our blogging team and getting paid to write about subjects you’re passionate about, please reach out to Sam via email at samwoolfe@gmail.com

share your toughts

Join the Conversation.

0 Comments

Inline Feedbacks

View all comments

9 minute read

In his book The Weird and the Eerie, cultural theorist Mark Fisher analyses the concept of the 'weird'. Sam Woolfe applies Fisher's analysis to psychedelic states.

09 Feb, 2026

Opinion | Psychedelics and Mark Fisher’s Theory of the Weird

Sam Woolfe

13 minute read

Un aperçu objectif du protoxyde d'azote, examinant sa normalisation croissante, ses effets puissants, son attrait, ses risques et son histoire.

07 Feb, 2026

Guides | Le gaz hilarant : Le protoxyde d’azote (N2O)

Nuit

13 minute read

Nuit compare les expériences de LSA issues de deux sources de semences, contextualisées par l'histoire et la science, dans le but de présenter une vision équilibrée des effets variables, des incertitudes, des risques et des enseignements de la LSA.

05 Feb, 2026

Personal Stories | Le LSA : la version naturelle du LSD ?

Nuit

12 minute read

Stroke, traumatic brain injury, and neurodegenerative diseases are leading, interconnected causes of global disability and economic burden with limited effective treatments. Sam Gandy highlights the potential of psychedelics as novel therapies to promote brain repair and recovery.

03 Feb, 2026

Science | Can Psychedelics Help Mend Broken and Ailing Brains?

Sam Gandy

11 minute read

The ancient, subterranean networks of fungi underpin life on Earth and are now emerging as a powerful foundation for future sustainable biotechnologies.

01 Feb, 2026

Science | Beyond the Trip: How Fungi Are Engineering Our Future

David Blackbourn

8 minute read

Dans la deuxième partie de ce guide sur l'influence du dosage sur les expériences psychédéliques, Eliacide examine les combinaisons de drogues et les expériences qui ne visent pas à dissoudre l'ego.

30 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 2)

Eliacide

9 minute read

Eliacide explique que le dosage des médicaments est très subjectif et doit être choisi en fonction du niveau d'expérience personnel et du contexte souhaité, avertissant que les débutants doivent éviter les doses élevées et encourageant les individus à trouver leur propre « juste milieu » plutôt que de considérer tout conseil comme absolu.

28 Jan, 2026

Guides | L’influence du dosage sur les expériences psychédéliques (Partie 1)

Eliacide

9 minute read

Real-world data confirms the extremely low physical risk of psychedelics; the NHS and FDA intensify their scrutiny of clinical rollout; and we see expanding legal momentum in the US, as well as a shift towards shorter-acting compounds and even non-hallucinogenic, virtual alternatives.

26 Jan, 2026

All Articles | PSYCH NEWS – 26/01/2026

David Blackbourn

12 minute read

Nuit s'entretient avec Andrés Gómez, chercheur en conscience à l'Institut de recherche Qualia, qui fait le lien entre la science informatique, les récits expérientiels, les traditions contemplatives orientales et la recherche psychédélique.

25 Jan, 2026

Personal Stories | Mon échange avec le chercheur Andrés Gómez Emilson

Nuit

10 minute read

John Robertson offers a practical guide to understanding the causes of non-responses to psychedelics and what to do to move beyond them safely and effectively.

24 Jan, 2026

Guides | The ‘Nada’ Experience: What To Do When Psychedelics Don’t Work (Part 2)

John Robertson

7 minute read

Alfredo Squillaro argues that informed use, drug checking, and education are far more effective than stigma and repression in reducing the risks of psychoactive substance use.

22 Jan, 2026

Opinion | (Anti)prohibition, Psychonautics, and Designer Drugs

Alfredo Squillaro

11 minute read

Oli Genn-Bash reflects on the Western pursuit of an “authentic self,” using personal psychedelic experiences to question whether self-discovery is less about uncovering a fixed identity and more about cultivating a healthy relationship with the self that allows it to soften, open, and connect with others.

20 Jan, 2026

Self-Development | Discovering the Authentic Self Through Psychedelics

Oli Genn-Bash

9 minute read

Free parties can be understood as modern expressions of ancient ritual practices – akin to the Dionysian Mysteries – where music, dance, and psychoactive substances induce ecstatic states of consciousness.

18 Jan, 2026

Opinion | Dionysian Cults and Free Parties

Alfredo Squillaro

13 minute read

Nuit décrit son expérience du 2C-P comme un psychédélique puissant, à action lente et prolongée, appartenant à la famille des 2C-x – davantage comparable à une longue et exigeante randonnée qu'à un simple voyage.

16 Jan, 2026

Personal Stories | 2C-P : La charrette psychédélique

Nuit

11 minute read

Can psychedelics genuinely challenge and undermine the military-industrial complex by transforming consciousness, or do they risk being co-opted to merely help individuals psychologically adapt to an inherently violent and unjust system?

14 Jan, 2026

Opinion | Decentralised Minds: Can Psychedelics Undermine the Military Industrial Complex?

Oli Genn-Bash

11 minute read

Oli Genn-Bash explores the growing popularity of functional mushrooms, blending personal experience, research, and traditional perspectives to argue for a more holistic, respectful understanding of fungi.

12 Jan, 2026

Opinion | A Holistic and Spiritual Approach to Functional Mushrooms

Oli Genn-Bash

11 minute read

Despite bold promises surrounding psychedelics, a significant share of patients fail to meaningfully improve, revealing that non-response is a central – and often overlooked – challenge in psychedelic therapy.

10 Jan, 2026

Science | Let’s Talk About Non-Responders in Psychedelic Therapy

Ed Prideaux

8 minute read

Psychedelic use is commonly divided into spiritual, therapeutic, and recreational categories whose meanings are unclear and unevenly valued, with recreational use often stigmatised despite having aspects that deserve reconsideration.

08 Jan, 2026

Opinion | In Defence of Recreational Psychedelic Use

Annabelle Abraham

15 minute read

The Immortality Key builds a sweeping psychedelic-religion narrative on evidence that its own primary scientific authority later rejected as methodologically flawed, undermining the book’s credibility despite its popular success.

06 Jan, 2026

History | Psychedelic Bullshit? An Evaluation of The Immortality Key

Ed Prideaux

10 minute read

Over the past year, the psychedelic field has seen unprecedented scientific and regulatory advances collide with bureaucratic barriers and venture capital pressures, revealing both rapid progress toward medical integration and the fragility – and cultural tension – of an emerging industry at a pivotal moment.

04 Jan, 2026

News & Updates | PSYCH NEWS 2025 – THE YEAR IN REVIEW

David Blackbourn

8 minute read

Martha Allitt unpacks the history of MK-ULTRA, a secret CIA program that conducted unethical experiments with LSD, hypnosis, and other techniques in an attempt to develop methods of mind control and psychological manipulation during the Cold War.

04 Jan, 2026

History | MK-ULTRA: A Macabre History of LSD and Mind Control

Martha Allitt

16 minute read

Ed Prideaux examines Elon Musk’s alleged drug use and public behaviour in the context of his immense political and technological influence.

02 Jan, 2026

Opinion | High on Power: How Much Does Ketamine Explain Elon Musk’s Erratic Behaviour?

Ed Prideaux

10 minute read

Psychedelics can help us rethink the “hard problem” of consciousness by challenging the materialist view that the brain generates experience.

30 Dec, 2025

Philosophy | Psychedelics and the Hard Problem of Consciousness

David Blackbourn

12 minute read

Nuit décrit le 2C-C comme un membre subtil et apaisant de la famille 2C-X, qui évoque de doux souvenirs d'expériences sereines et introspectives.

28 Dec, 2025

Guides | 2C-C : la version Stone du 2C-B ?

Nuit

4 minute read

Theories suggest that N,N-dimethyltryptamine (DMT) is released in our brains when we die – but what do we really know about this potent psychedelic and its endogenous role in the human body?

22 Dec, 2025

Science | The Endogenous DMT Narrative: Separating Fact From Fiction

Stephanie Price

11 minute read

While psychedelics get most of the limelight in discussions about altered states of consciousness, such states can also be accessed through more accessible and potentially safer means, particularly sound baths.

20 Dec, 2025

Spirituality | Sound Baths and Altered States

Oli Genn-Bash

9 minute read

David Blackbourn explores the history and present-day use of psychoactive substances in the Middle East, including the religious, social, and political factors that have influenced this usage.

18 Dec, 2025

History | Contemporary Psychoactive Drug Use in the Middle East

David Blackbourn

8 minute read

Iboga, a West African shrub traditionally used in the Bwiti spiritual tradition, is now being used for microdosing in the West.

16 Dec, 2025

Personal Stories | Microdosing Iboga: Why People Are Taking Tiny Amounts of a Hallucinogenic Shrub

Martha Allitt

5 minute read

Clinical trials typically evaluate psychedelics through short-term before-and-after measures to assess treatment efficacy, but longer-term and lifelong effects are harder to quantify.

14 Dec, 2025

Self-Development | The Long-Term Effects of Psychedelics Are Sometimes Ambiguous

Annabelle Abraham

11 minute read

While psychedelic insights may be valuable, they can be difficult to interpret and require a broader psychological, spiritual, philosophical, or cultural framework to determine whether they reflect genuine truth or mere subjective experience.

12 Dec, 2025

Self-Development | Psychedelics and Epistemic Authority: How Can We Trust Psychedelic Insights?

Oli Genn-Bash

Our Products

Related Products

SALE! -35%

1V-LSD 150mcg Blotters From

(145)

1cP-LSD 100mcg Blotters From 18.00

(137)

Tryptamine Mix and Match Pack (4 x 0.1g) €65.00

(1)

SALE! -35%

1V-LSD 10mcg Micro Pellets From

(44)

SALE! -35%

1V-LSD 225mcg Art Design Blotters From

(62)

1S-LSD 150mcg Blotters From 29.00

(18)

1cP-LSD 150mcg Art Design Blotters From 25.00

(74)

SALE! -35%

1V-LSD 225mcg Pellets From

(26)

1cP-LSD 10mcg Micro Pellets From 15.00

(23)

1D-LSD 225mcg Pellets (1T-LSD) From 42.00

(13)

5-MeO-DMT Freebase From 23.95

(36)

1S-LSD 10mcg Micro Pellets €20.00

(3)

O-PCE HCL From 17.50

(25)

1cP-LSD 20mcg Micro Blotters From 18.00

(28)

1cP-LSD 150mcg Pellets From 25.00

(13)

see all products

Earn
Affiliates

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Comment on an article

50

Check out our Community Blog and get involved with the conversation. You will be awarded 50 x ChemCoins for each comment up to a limit of 250 total ChemCoins.
Leave a product review

50

Have you purchased any of our products? Reviews and reports are so important to the community. Share your honest opinion, and we’ll reward you with 50 ChemCoins for each review!
Complete an order

X

Every time you complete an order with us, you’ll be awarded ChemCoins for each Euro spent.

Welcome to Chemical Collective.

Create an account to earn 200 welcome points.

create account

Already have an account? Sign in

Become an affiliate!

Earn commission every time someone makes a purchase through your link.

When you become an affiliate, you will be allocated a unique link to share with your friends, followers, subscribers, or Aunt Susan.

You can choose to payout the commission earned once per month, or save it up to receive on a rainy day! Commission earned is 5% of the total order value per referral.

Contact us to join the Chemical Collective family and become an affiliate.

Welcome toChemical Collective

PSYCH NEWS – 28/07/2025

By David Blackbourn

in this article

By David Blackbourn

MindMed MM-120 Receives FDA Breakthrough Designation for GAD

HHC Potency Found to be Comparable to THC

Psychoactive Drug Pollutants Accumulate in Fish Eyes

Sheffield University Studies Psychedelic Use Throughout History

5-MeO-DMT Nasal Spray Trial Shows Antidepressant Effect

Māori Representatives Present Indigenous Knowledge at Psychedelic Conference

Structure of LSD Bound to 5-HT2A Receptor Determined

Psilocybin Reduces Depression in Cancer Patients

By David Blackbourn

share your toughts

Join the Conversation.

Related articles

Related Products

Reward program

Comment on an article

Leave a product review

Complete an order

Become an affiliate!

Welcome to
Chemical Collective